Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
暂无分享,去创建一个
F. Tirode | M. Heymann | B. Pitard | D. Heymann | F. Redini | V. Trichet | F. Lamoureux | J. Amiaud | C. Charrier | G. Picarda | E. Matouš
[1] H. Knowles,et al. Ewing sarcoma cells express RANKL and support osteoclastogenesis , 2011, The Journal of pathology.
[2] M. Heymann,et al. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] O. Delattre,et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.
[4] D. Scherman,et al. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models , 2010, Cancer Gene Therapy.
[5] M. Dimopoulos,et al. RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases , 2009, Expert opinion on biological therapy.
[6] P. Kostenuik,et al. Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] E. Miot-Noirault,et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. , 2009, Cancer research.
[8] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[9] N. Athanasou,et al. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma , 2007, British Journal of Cancer.
[10] E. Steliarova-Foucher,et al. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.
[11] E. Steliarova-Foucher,et al. Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978-1997): report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.
[12] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[13] B. Pitard,et al. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. , 2005, Human gene therapy.
[14] D. Escande,et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. , 2005, Human gene therapy.
[15] J. Thiery,et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. , 2005, Bone.
[16] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[17] M. Padrines,et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.
[18] Colin R Dunstan,et al. A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] N. Kanomata,et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. , 2003, Cancer research.
[20] Y. Iwamoto,et al. Identification of p21 WAF1/CIP1 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003, The Journal of Biological Chemistry.
[21] P. Croucher,et al. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. , 2003, Cancer research.
[22] P. Croucher,et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.
[23] R. Kitazawa,et al. RANK ligand is a prerequisite for cancer‐associated osteolytic lesions , 2002, The Journal of pathology.
[24] D. Escande,et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. , 2002, Human gene therapy.
[25] F. Hamdy,et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.
[26] I. Holen,et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.
[27] J. Goldblum,et al. Expression of Fli-1, a Nuclear Transcription Factor, Distinguishes Vascular Neoplasms From Potential Mimics , 2001, The American journal of surgical pathology.
[28] L. Hofbauer,et al. Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .
[29] P. Kostenuik,et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.
[30] O. Delattre,et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression , 2001, Oncogene.
[31] P. Mantyh,et al. Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.
[32] L. Hofbauer,et al. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.
[33] D. Lacey,et al. Osteoprotegerin inhibits tumor‐induced osteoclastogenesis and bone tumor growth in osteopetrotic mice , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[34] J. Mönkkönen,et al. Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.
[35] H. Jürgens,et al. Deskriptive Epidemiologie der Ewing-Tumoren - Analysen der deutschen Patienten von (EI) CESS 1980-1997* , 1999 .
[36] K Yano,et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.
[37] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[38] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[39] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[40] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[41] C. Denny,et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Santamaría,et al. The neuroectodermal tumor of bone , 1984, The American journal of surgical pathology.
[43] J. Ewing. Diffuse endothelioma of bone , 1972 .
[44] A. Cabrera,et al. EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.
[45] G. Moriceau,et al. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. , 2010, Biochimica et biophysica acta.
[46] C. Albert,et al. Classics in oncology , 2006 .
[47] D. Escande,et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. , 2004, Nucleic acids research.
[48] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[49] J. Chirgwin,et al. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.
[50] H. Hense,et al. [Descriptive epidemiology of Ewing's tumor--analysis of German patients from (EI)CESS 1980-1997]. , 1999, Klinische Padiatrie.
[51] J. Ewing. Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. , 1972, CA: a cancer journal for clinicians.
[52] T. Martin,et al. Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .